𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Potential cure of acute myeloid leukemia : Analysis of 1069 consecutive patients in first complete remission

✍ Scribed by Masamitsu Yanada; Guillermo Garcia-Manero; Gautam Borthakur; Farhad Ravandi; Hagop Kantarjian; Elihu Estey


Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
160 KB
Volume
110
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

BACKGROUND.

Potential cure of acute myeloid leukemia (AML) is now a widely accepted idea, but it is uncertain whether there is heterogeneity in the failure rate in patients once they have been in complete remission (CR) for various periods of time.

METHODS.

The long‐term outcomes were analyzed in 1069 consecutive AML patients in first CR who were diagnosed and treated at the University of Texas M. D. Anderson Cancer Center between 1991 and 2003.

RESULTS.

The failure rates as yearly risk of treatment failure were 69.1 in the first year, 37.7 in the second year, 17.0 in the third year, 7.6 in the fourth year, and 6.6 in the fifth year, suggesting that 3 years from the CR date is a convenient time to consider patients potentially cured. The effect of cytogenetics on relapse‐free survival (RFS) remained constant throughout the first 3 years, whereas the effect of age increased with time. The probability of RFS for patients alive without disease recurrence at 3 years was 84.0% at 6 years. When the interaction between age and cytogenetics was examined for these patients, the outcomes of those with favorable cytogenetics were found to be excellent regardless of age. However, in the intermediate cytogenetic group, although patients aged <60 years had excellent outcomes, those aged β‰₯60 years were found to be at a substantial risk of disease recurrence even after 3 years of CR, with a 6‐year RFS rate of 56.5%. There were only 6 patients with adverse cytogenetics in this cohort.

CONCLUSIONS.

The results of the current study demonstrate that the risk of treatment failure differs over time according to a combination of cytogenetics and age. Cancer 2007. Published 2007 by the American Cancer Society.


πŸ“œ SIMILAR VOLUMES


Management of adult patients with acute
✍ Ron Ram; Anat Gafter-Gvili; Liat Vidal; Mical Paul; Isaac Ben-Bassat; Ofer Shpil πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 385 KB

## Abstract ## BACKGROUND: The optimal postremission therapy in adults with acute lymphoblastic leukemia (ALL) is still a matter of debate. The objective of this study was to compare the various potential therapeutic options for patients who achieved first complete remission. ## METHODS: The aut

A pilot study of interleukin-2 for adult
✍ Jorge E. Cortes; Hagop M. Kantarjian; Susan O'Brien; Francis Giles; Michael J. K πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 96 KB πŸ‘ 2 views

## BACKGROUND. Interleukin-2 (IL-2) has immunomodulatory effects, including stimulating the activity of cytotoxic T cells and natural killer cells, and inducing the generation of lymphokine-activated killer cells. The authors investigated whether IL-2 may improve the duration of complete remission